(269 days)
Not Found
Not Found
No
The summary describes an indirect immunofluorescence test kit and a microscope/software system for detecting ANCA. While it mentions a "EUROPattern system" and "suggested results," there is no explicit mention of AI, ML, deep learning, or any related terms in the provided text. The requirement for confirmation by trained personnel also suggests a traditional workflow rather than a fully automated AI-driven analysis.
No
This device is an in vitro diagnostic test for the qualitative or semi-quantitative determination of antibodies, used as an aid in diagnosis, not for treatment.
Yes
The device is described as "an aid in the diagnosis of ANCA associated vasculitides" which directly indicates a diagnostic purpose.
No
The device description is not available, but the intended use explicitly states the test kit is intended for use with the "EUROPattern microscope and software system," indicating a hardware component (microscope) is integral to the device's function.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- It is intended for use on human specimens (serum).
- It is used to determine the presence of specific substances (anti-neutrophil cytoplasmic antibodies, anti-MPO, anti-GBM antibodies) in these specimens.
- The results are used as an aid in the diagnosis of a disease (ANCA associated vasculitides).
- The test is performed in vitro (outside of the living body).
All of these characteristics align with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The EUROIMMUN IFA Granulocyte Mosaic EUROPattern is intended as an indirect immunofluorescence test for the qualitative or semi-quantitative determination of immunoglobulin class IgG anti-neutrophil cytoplasmic antibodies (ANCA) in human serum. It is used as an aid in the diagnosis of ANCA associated vasculitides, in conjunction with other laboratory and clinical findings. The EUROIMMUN IFA Granulocyte Mosaic EUROPattern test kit is intended for use with the EUROPattern microscope and software system. All suggested results obtained with the EUROPattern system must be confirmed by trained personnel.
The EUROIMMUN EUROPLUS Granulocyte Mosaic EUROPattern is intended as an indirect immunofluorescence test for the qualitative or semi-quantitation of immunoglobulin class IgG anti-neutrophil cytoplasmic antibodies (ANCA) and the qualitative determination of IgG anti-MPO, and, if included, anti-GBM antibodies in human serum. It is used as an aid in the diagnosis of ANCA associated vasculitides, in conjunction with other laboratory and clinical findings. The EUROIMMUN EUROPLUS Granulocyte Mosaic EUROPattern test kit is intended for use with the EUROPattern microscope and software system. All suggested results obtained with the EUROPattern system must be confirmed by trained personnel.
Product codes
MOB, MVJ, PIV
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.5660 Multiple autoantibodies immunological test system.
(a)
Identification. A multiple autoantibodies immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoantibodies (antibodies produced against the body's own tissues) in serum and other body fluids. Measurement of multiple autoantibodies aids in the diagnosis of autoimmune disorders (disease produced when the body's own tissues are injured by autoantibodies).(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image contains the logos of the U.S. Department of Health & Human Services and the U.S. Food & Drug Administration (FDA). The Department of Health & Human Services logo is on the left, and the FDA logo is on the right. The FDA logo is a blue square with the letters "FDA" in white, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue.
May 24, 2018
EUROIMMUN US, Inc. Michael Locke Director of Regulatory Affairs & Quality Management 1 Bloomfield Avenue Mountain Lakes. New Jersey 07046
Re: K172582
Trade/Device Name: EUROIMMUN IFA Granulocyte Mosaic EUROPattern EUROIMMUN EUROPLUS Granulocyte Mosaic EUROPattern Regulation Number: 21 CFR 866.5660 Regulation Name: Multiple autoantibodies immunological test system Regulatory Class: Class II Product Code: MOB, MVJ, PIV Dated: August 28, 2017 Received: August 28, 2017
Dear Michael Locke:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
1
801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Kelly Oliner -S
For
Lea Carrington Director Division of Immunology and Hematology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K172582
Device Name
EUROIMMUN IFA Granulocyte Mosaic™ EUROPattern & EUROIMMUN EUROPLUS Granulocyte Mosaic™ EUROPattern
Indications for Use (Describe)
The EUROIMMUN IFA Granulocyte Mosaic EUROPattern is intended as an indirect immunofluorescence test for the qualitative or semi-quantitative determination of immunoglobulin class IgG anti-neutrophil cytoplasmic antibodies (ANCA) in human serum. It is used as an aid in the diagnosis of ANCA associated vasculitides, in conjunction with other laboratory and clinical findings. The EUROIMMUN IFA Granulocyte Mosaic EUROPattern test kit is intended for use with the EUROPattern microscope and software system. All suggested results obtained with the EUROPattern system must be confirmed by trained personnel.
The EUROIMMUN EUROPLUS Granulocyte Mosaic EUROPattern is intended as an indirect immunofluorescence test for the qualitative or semi-quantitation of immunoglobulin class IgG anti-neutrophil cytoplasmic antibodies (ANCA) and the qualitative determination of IgG anti-MPO, and, if included, anti-GBM antibodies in human serum. It is used as an aid in the diagnosis of ANCA associated vasculitides, in conjunction with other laboratory and clinical findings. The EUROIMMUN EUROPLUS Granulocyte Mosaic EUROPattern test kit is intended for use with the EUROPattern microscope and software system. All suggested results obtained with the EUROPattern system must be confirmed by trained personnel.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."